175 related articles for article (PubMed ID: 35477740)
1. Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy.
Pérez-Martelo M; González-García A; Vidal-Ínsua Y; Blanco-Freire C; Brozos-Vázquez EM; Abdulkader-Nallib I; Álvarez-Fernández J; Lázare-Iglesias H; García-Martínez C; Betancor YZ; Sánchez-Ares M; Tubío JMC; Vázquez-Rivera F; Candamio-Folgar S; López-López R; Ruiz-Bañobre J
Sci Rep; 2022 Apr; 12(1):6893. PubMed ID: 35477740
[TBL] [Abstract][Full Text] [Related]
2. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
3. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Fucà G; Guarini V; Antoniotti C; Morano F; Moretto R; Corallo S; Marmorino F; Lonardi S; Rimassa L; Sartore-Bianchi A; Borelli B; Tampellini M; Bustreo S; Claravezza M; Boccaccino A; Murialdo R; Zaniboni A; Tomasello G; Loupakis F; Adamo V; Tonini G; Cortesi E; de Braud F; Cremolini C; Pietrantonio F
Br J Cancer; 2020 Aug; 123(3):403-409. PubMed ID: 32424148
[TBL] [Abstract][Full Text] [Related]
4. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
Provenzano L; Lobefaro R; Ligorio F; Zattarin E; Zambelli L; Sposetti C; Presti D; Montelatici G; Ficchì A; Martinetti A; Arata A; Del Vecchio M; Lauria Pantano C; Formisano B; Bianchi GV; Capri G; de Braud F; Vernieri C; Fucà G
Ther Adv Med Oncol; 2023; 15():17588359231165978. PubMed ID: 37063779
[TBL] [Abstract][Full Text] [Related]
5. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
6. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor.
Chen X; Hong X; Chen G; Xue J; Huang J; Wang F; Ali WADS; Li J; Zhang L
Transl Oncol; 2022 Mar; 17():101338. PubMed ID: 34999541
[TBL] [Abstract][Full Text] [Related]
7. The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery.
Sato S; Shimizu T; Ishizuka M; Suda K; Shibuya N; Hachiya H; Iso Y; Takagi K; Aoki T; Kubota K
Surg Today; 2022 Aug; 52(8):1160-1169. PubMed ID: 35015151
[TBL] [Abstract][Full Text] [Related]
8. Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma.
Su Z; Tang J; He Y; Zeng WH; Yu Q; Cao XL; Zou GR
Oncol Lett; 2024 Jun; 27(6):252. PubMed ID: 38646495
[TBL] [Abstract][Full Text] [Related]
9. Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.
Chen Y; Gong L; Gu P; Hua Y; Sun Y; Ni S; Zhou X; Tang Z
BMC Cancer; 2023 Oct; 23(1):944. PubMed ID: 37803437
[TBL] [Abstract][Full Text] [Related]
10. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
11. Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
Kayar R; Bastug Y; Tokuc E; Topaktas R; Akyurek EA; Kayar K; Artuk I; Ozturk M
Int Urol Nephrol; 2024 Feb; 56(2):509-518. PubMed ID: 37773579
[TBL] [Abstract][Full Text] [Related]
12. The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.
Fucà G; Beninato T; Bini M; Mazzeo L; Di Guardo L; Cimminiello C; Randon G; Apollonio G; Bisogno I; Del Vecchio M; Lauria Pantano C; Di Nicola M; de Braud F; Del Vecchio M
Target Oncol; 2021 Jul; 16(4):529-536. PubMed ID: 34076798
[TBL] [Abstract][Full Text] [Related]
13. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.
Topkan E; Kucuk A; Ozkan EE; Ozturk D; Besen AA; Mertsoylu H; Pehlivan B; Selek U
Discov Oncol; 2023 Dec; 14(1):230. PubMed ID: 38091179
[TBL] [Abstract][Full Text] [Related]
14. Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study.
Chang J; Lin G; Ye M; Tong D; Zhao J; Zhu D; Yu Q; Zhang W; Li W
BMC Cancer; 2019 Jan; 19(1):15. PubMed ID: 30612568
[TBL] [Abstract][Full Text] [Related]
15. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
Yekedüz E; Tural D; Ertürk İ; Karakaya S; Erol C; Ercelep Ö; Arslan Ç; Sever ÖN; Kılıçkap S; Şentürk Öztaş N; Küçükarda A; Can O; Öksüzoğlu B; Şendur MA; Karadurmuş N; Ürün Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3537-3546. PubMed ID: 35616728
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of pan-immune-inflammation value in colorectal cancer patients: A systematic review and meta-analysis.
Yang XC; Liu H; Liu DC; Tong C; Liang XW; Chen RH
Front Oncol; 2022; 12():1036890. PubMed ID: 36620576
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D
Ann Oncol; 2018 Apr; 29(4):924-930. PubMed ID: 29324972
[TBL] [Abstract][Full Text] [Related]
18. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
[TBL] [Abstract][Full Text] [Related]
19. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.
Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T
Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214
[TBL] [Abstract][Full Text] [Related]
20. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Ligorio F; Fucà G; Zattarin E; Lobefaro R; Zambelli L; Leporati R; Rea C; Mariani G; Bianchi GV; Capri G; de Braud F; Vernieri C
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
